Adial Pharmaceuticals, Inc. (ADIL)
6.36
-0.29
(-4.36%)
USD |
NASDAQ |
Sep 09, 09:56
Adial Pharmaceuticals Total Liabilities (Quarterly) : 67.47M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 67.47M |
| March 31, 2026 | 1.510M |
| December 31, 2025 | 1.522M |
| September 30, 2025 | 1.155M |
| June 30, 2025 | 1.211M |
| March 31, 2025 | 1.324M |
| December 31, 2024 | 1.014M |
| September 30, 2024 | 0.829M |
| June 30, 2024 | 0.6719M |
| March 31, 2024 | 0.5627M |
| December 31, 2023 | 0.6535M |
| September 30, 2023 | 0.5282M |
| June 30, 2023 | 0.4618M |
| March 31, 2023 | 2.462M |
| December 31, 2022 | 2.457M |
| September 30, 2022 | 2.333M |
| June 30, 2022 | 2.962M |
| March 31, 2022 | 3.256M |
| December 31, 2021 | 4.126M |
| September 30, 2021 | 3.246M |
| Date | Value |
|---|---|
| June 30, 2021 | 3.234M |
| March 31, 2021 | 3.008M |
| December 31, 2020 | 1.505M |
| September 30, 2020 | 1.093M |
| June 30, 2020 | 0.6819M |
| March 31, 2020 | 0.3898M |
| December 31, 2019 | 0.5391M |
| September 30, 2019 | 0.7769M |
| June 30, 2019 | 0.6266M |
| March 31, 2019 | 0.3292M |
| December 31, 2018 | 0.258M |
| September 30, 2018 | 0.3228M |
| June 30, 2018 | 1.481M |
| March 31, 2018 | 1.388M |
| December 31, 2017 | 1.032M |
| September 30, 2017 | 0.743M |
| June 30, 2017 | 0.6612M |
| March 31, 2017 | 0.3295M |
| December 31, 2016 | 0.255M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Eli Lilly & Co. | 108.40B |
| ANI Pharmaceuticals, Inc. | 896.90M |
| Corcept Therapeutics, Inc. | 182.93M |
| Veru, Inc. | 8.651M |
| Johnson & Johnson | 116.09B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 29.09M |
| Shareholders Equity (Quarterly) | -38.38M |
| Debt to Equity Ratio | -1.624 |
| Current Ratio | 5.633 |
| Net Debt Paydown Yield | -185.5% |